Anagrelide, page-47

Dont know what you call success nameuser but - the fact proof he has been a failure in most areas

What was the sp when SC and how many shares were on issue: ( SP around .05 - Shares on Issue 446,349,349)
How many shares on issue now 2,581,959,133 with a sp of .007

The appointment of Mr. Stephen Carter as a Director and ChiefExecutive Officer. Mr. Carter has extensive pharmaceutical industryexperience and has held a variety of senior positions with listedpublic companies including roles as both Chairman and ManagingDirector. He has extensive contacts and experience in the financialmarkets and the pharmaceutical industry and is well equipped tolead executive management through the commercialisation phase ofthe project.

Who else has come and gone:
Stewart
Wolfe
Robson
Harrigan (US Consultant)
PERTH, AUSTRALIA - 13 February 2014: SUDA LTD (ASX: SUD), a leader in oromucosal drug delivery, today announces that it has retained Mr. Donald Harrigan M.S.,RPh, Managing Partner at KAD Consultants, located in Dana Point, California USA. Mr.Harrigan and the team at KAD Consultants will provide advice on SUDA’s US regulatorystrategy and will serve as the Company’s US agent for communications with the FDA.

Torreya Partners
PERTH, AUSTRALIA – 13 June 2014: SUDA LTD (ASX: SUD), a leader in oro-mucosal drugdelivery, today announced that it has appointed Torreya Partners (Torreya) to lead thenegotiations to out-license or sell ArTiMist™, SUDA’s novel sublingual antimalarialtreatment. Torreya is an internationally renowned advisory company for pharmaceuticallicensing and trade sales with offices in New York and London. The firm has carried outover 500 transactions in the healthcare sector.
And a few others who i dont have names for
And this doesnt include the CABs for SUD -001 , SUD - 003 - and Artimist

Here is another failure

PERTH, AUSTRALIA – 26 August 2015: SUDA LTD (ASX: SUD) (SUDA), a leader in oromucosal drug delivery, is pleased to announce the acquisition of the 20% minority shareholding in SUDA’s subsidiary company, Malaria Research Company Pty Ltd (MRC),which was owned by UK-based ProtoPharma Ltd (PPL) and its parent London Pharma Ltd(LPL). MRC owns the rights to SUDA’s novel sublingual anti-malarial spray, ArTiMist™. PPL isselling its 20% shareholding in MRC to SUDA for A$1.2 million. This payment is in full and final settlement of all outstanding liabilities between the two companies. In addition, PPL and LPL have agreed not to compete with MRC's ArTiMist™ spray. This acquisition is an important step towards SUDA’s objective to commercialise ArTiMist™ through a collaboration or trade sale.